Treatment of experimental staphylococcal endocarditis due to a strain with reduced susceptibility in vitro to vancomycin: efficacy of ampicillin-sulbactam.

Abstract

We evaluated several 3-day antimicrobial regimens in the treatment of experimental endocarditis caused by an oxacillin-resistant Staphylococcus aureus strain exhibiting intermediate susceptibility in vitro to vancomycin (VISA). Neither vancomycin alone nor trovafloxacin exhibited in vivo efficacy; addition of amikacin to vancomycin yielded a modest in vivo effect. In contrast, the combination of ampicillin and sulbactam was highly effective in vivo, causing a mean decrease in VISA vegetation densities of >5 log(10) CFU/g versus those of untreated controls.

• Authors: M Backo, E Gaenger, A Burkart, Y L Chai, A S Bayer
• Journal: Antimicrobial agents and chemotherapy (Antimicrob Agents Chemother) Vol. 43 Issue 10 Pg. 2565-8 (Oct 1999) ISSN: 0066-4804 [Print] United States
• PMID: 10508047 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Anti-Bacterial Agents
• sultamicillin
• Vancomycin
• Ampicillin
• Sulbactam

Topics

• Ampicillin (therapeutic use)
• Animals
• Anti-Bacterial Agents (pharmacology)
• Disease Models, Animal
• Drug Resistance, Microbial
• Drug Therapy, Combination (therapeutic use)
• Endocarditis, Bacterial (drug therapy, microbiology)
• Microbial Sensitivity Tests
• Rabbits
• Staphylococcal Infections (drug therapy)
• Staphylococcus aureus (drug effects)
• Sulbactam (therapeutic use)
• Vancomycin (pharmacology)